Finoriq research workspace
Indivior Pharmaceuticals, Inc. (INDV) Historical Metrics
Indivior Pharmaceuticals, Inc. engages in the development, manufacture, and sale of. Review INDV fundamentals, ratios, and historical filing metrics on Finoriq.
Company Snapshot
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
- Company
- Indivior Pharmaceuticals, Inc. (INDV)
- Ticker
- INDV
- Market Cap
- $4.9B
- Latest Price
- $39.55
- Industry
- Biotech & Pharma
Indivior Pharmaceuticals, Inc. (INDV) Current Valuation Metrics
Static valuation preview for Indivior Pharmaceuticals, Inc. (INDV). Market data retrieved 2026-07-08. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/EMarket cap divided by latest TTM net income. | 20.3x | Net Income | TTM Q1 2026 |
| P/SMarket cap divided by latest TTM revenue. | 3.94x | Revenue | TTM Q1 2026 |
| Earnings YieldLatest TTM net income divided by market cap. | 4.9% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -2.2% | Operating Cash Flow | TTM Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.